Eli Lilly and Company $LLY Shares Purchased by Concord Asset Management LLC VA

Concord Asset Management LLC VA increased its stake in Eli Lilly and Company (NYSE:LLY) by 20.2% during the 2nd quarter, Holdings Channel reports. The fund owned 3,652 shares of the company’s stock after purchasing an additional 614 shares during the quarter. Concord Asset Management LLC VA’s holdings in Eli Lilly and Company were worth $2,847,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of LLY. Sequoia Financial Advisors LLC boosted its position in shares of Eli Lilly and Company by 19.0% during the 2nd quarter. Sequoia Financial Advisors LLC now owns 140,201 shares of the company’s stock worth $109,291,000 after acquiring an additional 22,410 shares in the last quarter. Total Clarity Wealth Management Inc. raised its position in Eli Lilly and Company by 3.9% during the 2nd quarter. Total Clarity Wealth Management Inc. now owns 969 shares of the company’s stock worth $756,000 after buying an additional 36 shares during the last quarter. Vest Financial LLC increased its stake in shares of Eli Lilly and Company by 39.3% during the second quarter. Vest Financial LLC now owns 9,150 shares of the company’s stock worth $7,133,000 after acquiring an additional 2,580 shares during the period. Montrusco Bolton Investments Inc. acquired a new stake in shares of Eli Lilly and Company in the 2nd quarter valued at approximately $46,591,000. Finally, Lion Street Advisors LLC grew its stake in shares of Eli Lilly and Company by 4.1% during the 2nd quarter. Lion Street Advisors LLC now owns 531 shares of the company’s stock worth $414,000 after purchasing an additional 21 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Insiders Place Their Bets

In other news, Director J Erik Fyrwald acquired 1,565 shares of the business’s stock in a transaction on Tuesday, August 12th. The shares were purchased at an average price of $642.33 per share, for a total transaction of $1,005,246.45. Following the acquisition, the director directly owned 74,578 shares of the company’s stock, valued at $47,903,686.74. This represents a 2.14% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Daniel Skovronsky bought 1,000 shares of the company’s stock in a transaction dated Tuesday, August 12th. The shares were acquired at an average cost of $634.40 per share, for a total transaction of $634,400.00. Following the completion of the transaction, the executive vice president owned 137,660 shares of the company’s stock, valued at approximately $87,331,504. The trade was a 0.73% increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders bought 4,514 shares of company stock valued at $2,894,841. Corporate insiders own 0.14% of the company’s stock.

Eli Lilly and Company Trading Down 1.8%

Shares of LLY opened at $818.60 on Tuesday. The stock has a market cap of $774.77 billion, a PE ratio of 53.50, a P/E/G ratio of 1.18 and a beta of 0.47. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $937.00. The stock’s 50-day moving average is $743.43 and its two-hundred day moving average is $765.54.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. During the same period last year, the business posted $3.92 EPS. The company’s revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Equities analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. Cantor Fitzgerald set a $925.00 price objective on shares of Eli Lilly and Company and gave the stock an “overweight” rating in a research report on Thursday. Guggenheim raised their target price on shares of Eli Lilly and Company from $875.00 to $948.00 and gave the stock a “buy” rating in a research report on Wednesday, October 8th. DZ Bank raised shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 14th. Leerink Partners reaffirmed a “market perform” rating and set a $715.00 price target on shares of Eli Lilly and Company in a research note on Thursday, August 7th. Finally, Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Eli Lilly and Company in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and ten have given a Hold rating to the company’s stock. According to MarketBeat.com, Eli Lilly and Company currently has an average rating of “Moderate Buy” and an average price target of $948.06.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.